In last trading session, Protara Therapeutics Inc (NASDAQ:TARA) saw 0.33 million shares changing hands with its beta currently measuring 1.66. Company’s recent per share price level of $3.90 trading at -$0.42 or -9.83% at ring of the bell on the day assigns it a market valuation of $143.39M. That closing price of TARA’s stock is at a discount of -168.72% from its 52-week high price of $10.48 and is indicating a premium of 58.97% from its 52-week low price of $1.60. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.21 million shares which gives us an average trading volume of 281.06K if we extend that period to 3-months.
For Protara Therapeutics Inc (TARA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.48 in the current quarter.
Protara Therapeutics Inc (NASDAQ:TARA) trade information
Upright in the red during last session for losing -9.83%, in the last five days TARA remained trading in the red while hitting it’s week-highest on Monday, 03/31/25 when the stock touched $3.90 price level, adding 14.66% to its value on the day. Protara Therapeutics Inc’s shares saw a change of -26.14% in year-to-date performance and have moved -14.85% in past 5-day. Protara Therapeutics Inc (NASDAQ:TARA) showed a performance of -0.51% in past 30-days. Number of shares sold short was 1.78 million shares which calculate 6.28 days to cover the short interests.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 55.31% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 19.72% while estimates for its earnings growth in next 5 years are of 2.52%.
Protara Therapeutics Inc (NASDAQ:TARA)’s Major holders
Insiders are in possession of 3.46% of company’s total shares while institution are holding 86.66 percent of that, with stock having share float percentage of 89.77%. Investors also watch the number of corporate investors in a company very closely, which is 86.66% institutions for Protara Therapeutics Inc that are currently holding shares of the company. OPALEYE MANAGEMENT INC. is the top institutional holder at TARA for having 2.3 million shares of worth $5.3 million. And as of 2024-06-30, it was holding 20.1758 of the company’s outstanding shares.
The second largest institutional holder is RA CAPITAL MANAGEMENT, L.P., which was holding about 1.9 million shares on 2024-06-30. The number of shares represents firm’s hold over 16.6361 of outstanding shares, having a total worth of $3.95 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.02 shares of worth $3.99 million or 2.78% of the total outstanding shares. The later fund manager was in possession of 296.0 shares on Dec 31, 2024 , making its stake of worth around $1.15 million in the company or a holder of 0.81% of company’s stock.
